Abstract:Liver fibrosis is a major global health concern. Management of chronic liver disease is severely restricted in clinics due to ineffective treatment approaches. However, a lack of targeted therapy may aggravate this condition. Asiatic acid (AA), a pentacyclic triterpenoid acid, can effectively protect the liver from hepatic disorders. However, the pharmaceutical application of AA is limited by low oral bioavailability and poor targeting efficiency. This study synthesized a novel liver-targeting material from PEG-SA, chemically linked to ursodeoxycholic acid (UA), and utilized it to modify AA nanostructured lipid carriers (UP-AA-NLC) with enhanced targeting and improved efficacy. The formulation of UP-AA-NLC was optimized via the Box-Behnken Experimental Design (BBD) and characterized by size, zeta potential, TEM, DSC, and XRD. Furthermore, <i>in vitro</i> antifibrotic activity and proliferation of AA and NLCs were assessed in LX-2 cells. The addition of UP-AA-NLC significantly stimulated the TGF-beta1-induced expression of α-SMA, FN1, and Col I α1. <i>In vivo</i> near-infrared fluorescence imaging and distribution trials in rats demonstrated that UP-AA-NLC could significantly improve oral absorption and liver-targeting efficiency. Oral UP-AA-NLC greatly alleviated carbon tetrachloride-induced liver injury and fibrosis in rats in a dosage-dependent manner, as reflected by serum biochemical parameters (AST, ALT, and ALB), histopathological features (H&E and Masson staining), and antioxidant activity parameters (SOD and MDA). Also, treatment with UP-AA-NLC lowered liver hydroxyproline levels, demonstrating a reduction of collagen accumulation in the fibrotic liver. Collectively, optimized UP-AA-NLC has potential application prospects in liver-targeted therapy and holds great promise as a drug delivery system for treating liver diseases.

Bile acid-based polydrug nanoparticles for the treatment of acute liver injury

Novel reduced heteropolyacid nanoparticles for effective treatment of drug-induced liver injury by manipulating reactive oxygen and nitrogen species and inflammatory signals

Preclinical Validation of Silibinin/albumin Nanoparticles As an Applicable System Against Acute Liver Injury.

Amelioration of Acute Alcoholic Liver Injury via Attenuating Oxidative Damage and Modulating Inflammation by Means of Ursodeoxycholic Acid-Zein Nanoparticles

Visualization of therapeutic intervention for acute liver injury using low-intensity pulsed ultrasound-responsive phase variant nanoparticles

Self-Propelled Ultrasmall AuNPs-Tannic Acid Hybrid Nanozyme with ROS-Scavenging and Anti-Inflammatory Activity for Drug-Induced Liver Injury Alleviation.

Liver-Targeted Nanoparticles Loaded with Cannabidiol Based on Redox Response for Effective Alleviation of Acute Liver Injury

Polydopamine nanoparticles as a non-pharmaceutical tool in the treatment of fatty liver disease

Responsive Oligochitosan Nano-Vesicles with Ursodeoxycholic Acid and Exenatide for NAFLD Synergistic Therapy Via SIRT1.

Ros-responsive Dextran-Phenylboronic Acid-Silibinin Nanoparticles for Targeting Delivery of BAPTA-AM to Effectively Eliminate Calcium Overload-Mediated Inflammatory Cascades and Mitochondrial Apoptosis: Alleviating Acute Liver Injury

Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases

Natural ursolic acid based self-therapeutic polymer as nanocarrier to deliver natural resveratrol for natural therapy of acute kidney injury

Self-Assembled Poly(rosmarinic acid) Nanoantioxidant for Enhanced Acute Liver Injury Treatment

Bioinspired menstrual blood‐derived stem cells‐conditioned medium/polymersome nanoparticles for the treatment of carbon tetrachloride‐induced acute liver failure in mice

Hepatocyte-targeted hyaluronic acid-polyethyleneimine conjugates for acute liver injury therapy by ROS elimination and inflammation modulation

Polymeric Nanomedicines for the Treatment of Hepatic Diseases

Preparation of oxymatrine n-butyl polycyanoacrylate nanoparticles and its hepatoprotective effects in ob/ob mice

Construction of Phlorotannin-Based Nanoparticles for Alleviating Acute Liver Injury

Liver-targeted delivery of asiatic acid nanostructured lipid carrier for the treatment of liver fibrosis

The Hepatic-Targeted, Resveratrol Loaded Nanoparticles for Relief of High Fat Diet-Induced Nonalcoholic Fatty Liver Disease.

Self-Sulfhydrated, Nitro-Fixed Albumin Nanoparticles as a Potent Therapeutic Agent for the Treatment of Acute Liver Injury